Cited by 16Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease PreventionChronic Kidney Disease and Diabetes

Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial

Open access
Chen, Jing, Hamm, L. Lee, Bundy, Joshua D., Kumbala, Damodar R., Bodana, Shirisha, Chandra, Sehgal, Chen, Chung-Shiuan, Starcke, Charlton C. +15 more·2020·Clinical Journal of the American Society of Nephrology

Abstract

Background and objectives Endothelial dysfunction is common among patients with CKD. We tested the efficacy and safety of combination treatment with sodium nitrite and isoquercetin on biomarkers of endothelial dysfunction in patients with CKD. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled phase 2 pilot trial enrolled 70 patients with predialysis CKD. Thirty-five were randomly assigned to combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks, and 35 were randomly assigned to placebo. The primary outcome was mean change in flow-mediated vasodilation over the 12-week intervention. Secondary and safety outcomes included biomarkers of endothelial dysfunction, inflammation, and oxidative stress as well as kidney function, methemoglobin, and adverse events. Intention-to-treat analysis was conducted. Results Baseline characteristics, including age, sex, race, cigarette smoking, history of hypertension and diabetes, use of renin-angiotensin system blockers, BP, fasting glucose, lipid profile, kidney function, urine albumin-creatinine ratio, and endothelial biomarkers, were comparable between groups. Over the 12-week intervention, flow-mediated vasodilation increased 1.1% (95% confidence interval, −0.1 to 2.3) in the treatment group and 0.3% (95% confidence interval, −0.9 to 1.5) in the placebo group, and net change was 0.8% (95% confidence interval, −0.9 to 2.5). In addition, changes in biomarkers of endothelial dysfunction (vascular adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, vWf, endostatin, and asymmetric dimethylarginine), inflammation (TNF- α , IL-6, C-reactive protein, IL-1 receptor antagonist, and monocyte chemoattractant protein-1), and oxidative stress (oxidized LDL and nitrotyrosines) were not significantly different between the two groups. Furthermore, changes in eGFR, urine albumin-creatinine ratio, methemoglobin, and adverse events were not significantly different between groups. Conclusions This randomized phase 2 pilot trial suggests that combination treatment with sodium nitrite and isoquercetin did not significantly improve flow-mediated vasodilation or other endothelial function biomarkers but also did not increase adverse events compared with placebo among patients with CKD. Clinical Trial registry name and registration number: Nitrite, Isoquercetin, and Endothelial Dysfunction (NICE), NCT02552888

Integrity signals

Registry

Crossref · 10.2215/cjn.02020220

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chen, J., Hamm, L. L., Bundy, J. D., Kumbala, D. R., Bodana, S., Chandra, S., Chen, C.-S., Starcke, C. C., Guo, Y., Schaefer, C. M., Lustigova, E., Mahone, E., Vadalia, A. M., Livingston, T., Obst, K., Hernandez, J., Bokhari, S. R., Kleinpeter, M., Alper, A. B., Lukitsch, I., He, H., Nieman, D. C., & He, J.
Affiliations
  • Tulane University (US)
  • Renal Associates of Baton Rouge, Baton Rouge, Louisiana
  • Ochsner Health System (US)
  • University of Pennsylvania (US)
  • Appalachian State University (US)
Venue
Clinical Journal of the American Society of Nephrology
Published
2020-10-06
Volume
15
Issue
11
Pages
1566-1575
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W3091949616
Cited by
16
References
47
Citations by year
2026: 2 · 2025: 6 · 2024: 2 · 2023: 2 · 2022: 4
FWCI
0.90
Type
journal article
Language
en
Open access
Locations
  • Clinical Journal of the American Society of Nephrology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of General Medical Sciences of the National Institutes of Health (U54 GM104940)
  • National Institute of Health (NIH); National Institute of General Medical Sciences (P20 GM109036)
  • NIH; NIGMS (P30-GM103337)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
sodium nitrite, isoquercitrin, endothelial dysfunction, chronic kidney disease, flow-mediated dilation, pre-dialysis CKD, oxidative stress, inflammation, methemoglobin, asymmetric dimethylarginine, endostatin, nitric oxide donors, flavonoids, combination therapy, endothelial markers, oxidative stress biomarkers, inflammatory markers, EGFR
MeSH terms
Aged, Antioxidants, Arginine, Drug Therapy, Combination, Endothelium, Female, Glomerular Filtration Rate, Amine Oxidase (Copper-Containing), Humans, Inflammation, Male, Middle Aged, Pilot Projects, Quercetin, Sodium Nitrite, Vasodilation, von Willebrand Factor, Biomarkers, Cell Adhesion Molecules, Oxidative Stress, Intercellular Adhesion Molecule-1, E-Selectin, Endostatins, Renal Insufficiency, Chronic, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review